Naoto Azuma

Naoto Azuma

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2018 in Inflammation and Regeneration
Verified
Journal Article
Open access
PDF file
NANaoto Azuma
Naoto Azuma
YKYoshinori Katada
Yoshinori Katada
HSHajime Sano
Hajime Sano
Sjögren’s syndrome (SS) is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, especially the salivary and lacrimal glands. As a result of salivary gland dysfunction, most patients with SS have xerostomia related to a reduced salivary flow rate. In addition to the discomfort due to xerostomia, dry mouth can cause various intraoral manifestations such as refractory stomatitis, ulcer, and atrophic changes in the oral mucosa and tongue, and the patient’s quality of life (QoL) is severely impaired. These manifestations are believed to be caused mainly by a decrease in the clearance in the oral cavity owing to hyposalivation. However, because saliva has several beneficial physiological effects on the intraoral environment, qualitative changes in sialochemistry should also be considered a cause of the refractory intraoral manifestations in SS. Salivary epidermal growth factor (EGF) is considered an important cytoprotective factor against injuries. It contributes to wound healing in the oral cavity and to maintenance of mucosal integrity in the oral cavity and gastrointestinal tract. We evaluated changes in salivary EGF levels and assessed the association between salivary EGF levels and the severity of intraoral manifestations in patients with SS. The following novel findings were obtained: (1) salivary EGF levels in SS patients were significantly lower than those in non-SS patients; (2) salivary EGF levels as well as the salivary flow rate decreased with the progression of SS; (3) with prolonged SS disease duration, salivary EGF levels decreased more rapidly than the salivary flow rate; and (4) decreases in salivary EGF levels significantly correlated with exacerbation of the oral health-related QoL in patients with SS. The deterioration in saliva quality as well as lower intraoral clearance by hyposalivation could play a role in the pathogenesis of refractory intraoral manifestations in patients with SS. Our findings suggest a new target for therapeutic intervention for SS.

30 July 2020 in Modern Rheumatology
Verified
Journal Article
Closed access
NANaoto Azuma
Naoto Azuma
YKYoshinori Katada
Yoshinori Katada
TYTakahiro Yoshikawa
Takahiro Yoshikawa
YYYuichi Yokoyama
Yuichi Yokoyama
ANAki Nishioka
Aki Nishioka
KMKiyoshi Matsui
Kiyoshi Matsui
Objectives: To assess oral health-related quality of life (OHRQoL) and changes in OHRQoL in three years of patients with Sjögren’s symdrome (SS). Methods: Thirty-five SS patients and 23 non-SS individuals were enrolled. OHRQoL were quantitatively evaluated using the shortened Oral Health Impact Profile (OHIP-14). After three years, 22 patients and 14 controls tool the OHIP-14 survey again. Results: The SS group had a significantly higher OHIP-14 score, which indicated a lower OHRQoL, than the non-SS group. Among individual questions in the OHIP-14, scores for “trouble pronouncing words”, “uncomfortable to eat foods”, “self-conscious”, and “diet unsatisfactory” were markedly higher in the SS group than in the non-SS group. The OHIP-14 score significantly increased in three years in the SS group. Furthermore, there was an inverse correlation between the change rate of salivary flow rate and change of OHIP-14 scores in three years in patients with SS whose OHIP-14 score increased. Scores for “irritable with other people”, “difficulty doing usual jobs”, “felt life less satisfying”, and “unable to function” significantly increased in three years. Conclusions: In SS, OHRQoL decreased in three years, which was associated with a decrease in saliva secretion. Moreover, troubles related to psychosocial aspects in SS patients were found to intensify over time.

27 May 2015 in Modern Rheumatology
Verified
Journal Article
Closed access
PDF file
NANaoto Azuma
Naoto Azuma
YKYoshinori Katada
Yoshinori Katada
SKSachie Kitano
Sachie Kitano
MSMasahiro Sekiguchi
Masahiro Sekiguchi
MKMasayasu Kitano
Masayasu Kitano
HSHajime Sano
Hajime Sano
Objectives. To assess changes in salivary epidermal growth factor (EGF) levels within three years and investigate the correlation between these changes and the severity of intraoral manifestations in patients with Sjögren's syndrome (SS). Methods. Twenty-three SS patients (14 primary SS and 9 secondary SS) and 14 controls were followed up for three years. Salivary EGF concentration was measured using an enzyme-linked immunosorbent assay, and intraoral manifestations were evaluated using a short version of the Oral Health Impact Profile (OHIP-14). Changes in salivary flow rate, EGF level, and severity of intraoral manifestations were analyzed, along with associations among them. Results. The OHIP-14 score significantly increased and the total salivary EGF output significantly decreased after three years in the SS group (10.2 ± 8.8 vs. 12.6 ± 9.2, p = 0.040; 10158.4 ± 9820.9 vs. 8352.8 ± 7813.3 pg/10 min, p = 0.032), though the salivary flow rate did not change. The decrease in total EGF output was especially high in patients with long disease duration and poor oral health-related quality of life (OHRQoL). In patients with poor OHRQoL, the change in total EGF output significantly correlated with the OHIP-14 score (r = − 0.847, p = 0.008). However, there was no correlation between the change in salivary flow rate and the OHIP-14 score. Conclusions. The rapid decrease in salivary EGF level contributes to the progression of intraoral manifestations of SS.

10 April 2024 in Modern Rheumatology Case Reports
Verified
Journal Article
Open access
PDF file
NANaoto Azuma
Naoto Azuma
MNMasaru Natsuaki
Masaru Natsuaki
NHNaoaki Hashimoto
Naoaki Hashimoto
TATakeo Abe
Takeo Abe
SUSuzu Ueda
Suzu Ueda
KMKiyoshi Matsui
Kiyoshi Matsui
Alopecia associated with lupus erythematosus is broadly classified into reversible nonscarring alopecia seen in the acute phase, such as worsening of systemic lupus erythematosus (SLE) and cicatricial alopecia seen in chronic cutaneous lupus erythematosus represented by discoid lupus erythematosus (DLE). In DLE-induced alopecia, early therapeutic intervention before developing scarring alopecia is important, but the condition is often resistant to conventional treatment. Anifrolumab (ANI), a novel therapeutic agent for SLE that inhibits Type I interferon activity, has been shown to be effective against acute skin lesions, including alopecia, in patients with SLE. However, there are very few reports on the effect of ANI on alopecia due to DLE. We report on a 27-year-old Japanese woman with SLE whose alopecia due to chronic DLE was refractory to topical therapy and systemic therapy with oral glucocorticoid, multiple immunosuppressants, and belimumab for ∼8 years after onset and whose alopecia improved with ANI. ANI can be considered to be an effective treatment option in lupus patients presenting with alopecia due to DLE, even in the chronic refractory stage.

8 July 2022 in Immunological Medicine
Verified
Journal Article
Open access
KTKazuyuki Tsuboi
Kazuyuki Tsuboi
KNKazuteru Noguchi
Kazuteru Noguchi
MKMasayasu Kitano
Masayasu Kitano
TFTetsuya Furukawa
Tetsuya Furukawa
THTeppei Hashimoto
Teppei Hashimoto
KMKiyosshi Matsui
Kiyosshi Matsui
We examined whether serum B cell activating factor (BAFF) is useful for predicting the remission of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following rituximab treatment. We used the Birmingham Vasculitis Activity Score (BVAS) 2008 version 3 for the evaluation of 27 patients with AAV 6 months after rituximab treatment. Those with BVAS = 0 achieved remission, whereas those with BVAS score > 0 did not achieve remission. We considered changes in serum BAFF before rituximab treatment, 1 month after treatment, and 6 months after treatment. In the remission group, the serum BAFF increased consistently. In the non-achieved group, serum BAFF was within the normal range. In addition, there was no statistically significant difference between the two groups in terms of serum BAFF before and 1 month after rituximab treatment. However, the serum BAFF level at 6 months after rituximab treatment was significantly higher in the remission group than in the non-achieved group. If serum BAFF does not increase after 6 months of rituximab in AAV, it may be assumed that there are residual B cells and plasma cells in the tissues. Enhanced treatment targeting B cells, including re-administration of rituximab or the addition of other immunosuppressive drugs, should be considered.

1 January 2009 in Internal Medicine
Verified
Journal Article
Open access
PDF file
NANaoto Azuma
Naoto Azuma
NHNaoaki Hashimoto
Naoaki Hashimoto
AYAkihiro Yasumitsu
Akihiro Yasumitsu
KFKazuya Fukuoka
Kazuya Fukuoka
KYKazunori Yokoyama
Kazunori Yokoyama
HSHajime Sano
Hajime Sano
We report a case of cytomegalovirus (CMV) pneumonitis that presented as a cavitary lung lesion in a patient with systemic lupus erythematosus receiving immunosuppressive treatment. The lesion was confirmed by positive polymerase chain reaction (PCR) for CMV in bronchoalveolar lavage fluid (BALF) and CMV antigenemia. PCR for CMV in BALF was demonstrated to be useful for the diagnosis of CMV pneumonitis on the basis of high sensitivity and specificity. After initiating ganciclovir, the lesion gradually regressed. A cavitary lung lesion associated with CMV is extremely rare. This presentation suggests that the differential diagnosis of cavitary lung lesion in immunocompromised individuals should include CMV.